SCHEDULE 13G: BlackRock Discloses 5.4% Stake in Corvus Pharma
Beneficial Ownership Report
BlackRock, Inc. has reported a beneficial ownership of 5.4% of Corvus Pharmaceuticals Inc.'s common stock.
Summary
- BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in Corvus Pharmaceuticals Inc.
- As of September 30, 2025, BlackRock beneficially owns 4,015,510 shares of Corvus Pharmaceuticals' common stock.
- This ownership represents 5.4% of the total outstanding common stock of Corvus Pharmaceuticals Inc.
- BlackRock, Inc. holds sole voting power over 3,960,804 shares and sole dispositive power over 4,015,510 shares.
- No shared voting or dispositive power is reported by BlackRock, Inc. for these shares.
- The filing indicates that BlackRock's acquisition and holding of these securities are in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a strong positive or negative sentiment regarding the issuer's performance. The presence of a major institutional investor like BlackRock could be seen as a mild positive signal, but the filing itself is neutral in tone and content regarding Corvus's operational outlook.
Positives
- A major institutional investor like BlackRock, Inc. taking a significant stake (over 5%) can signal confidence in Corvus Pharmaceuticals Inc.'s long-term prospects.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Corvus Pharmaceuticals Inc.'s operations or financial performance.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing reflects a standard disclosure by a large institutional asset manager, BlackRock, Inc., indicating a passive investment position in Corvus Pharmaceuticals Inc. It does not provide specific insights into broader industry trends or competitive landscape, but rather signals BlackRock's investment allocation decisions within the biotechnology or pharmaceutical sector.
Comparison to Industry Standards
- This is a routine disclosure for institutional investors crossing the 5% beneficial ownership threshold, aligning with SEC regulations for Schedule 13G filings.
- BlackRock, Inc. is one of the world's largest asset managers, and its investment decisions are closely watched. While this filing is a passive disclosure, it indicates BlackRock's inclusion of Corvus Pharmaceuticals in its managed portfolios, similar to how other large funds like Vanguard or State Street disclose their holdings in various public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update (BlackRock Internal) | BlackRock, Inc. updated its internal Power of Attorney, appointing several individuals as attorneys-in-fact for executing ownership or control-person reporting requirements. This revokes a previous Power of Attorney dated April 30, 2023. | 2025-01-21 | This is an internal corporate governance update for BlackRock, Inc. to streamline its SEC filing processes and does not directly impact Corvus Pharmaceuticals Inc.'s corporate governance or management. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially influence market perception of the stock.
- Investment Professionals: Provides transparency into the ownership structure of Corvus Pharmaceuticals Inc. and BlackRock's investment strategy.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, now revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-09-30 | Date of event which required the filing of this statement (beneficial ownership threshold crossed). |
| 2025-10-17 | Date the Schedule 13G was signed by BlackRock, Inc. |
Keywords
Corvus Pharmaceuticals, BlackRock, Institutional Ownership, Schedule 13G, Common Stock, Beneficial Ownership, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.